NCT06136364View on ClinicalTrials.gov

CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

August 15, 2024

Study Completion Date

August 14, 2038

Conditions
T-lymphoblastic LymphomaT-ALL
Interventions
BIOLOGICAL

CAR-T

CAR-T immunotherapy targeting CD7+

Trial Locations (1)

Unknown

RECRUITING

Shanghai Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Hebei Senlang Biotechnology Inc., Ltd.

INDUSTRY

NCT06136364 - CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study | Biotech Hunter | Biotech Hunter